A Study of Pyrotinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: HER2 Positive Metastatic Breast Cancer
Interventions: DRUG: pyrotinib|DRUG: placebo|DRUG: Capecitabine
Sponsor: Jiangsu HengRui Medicine Co., Ltd.